CD14 and prostate cancer: Increased numbers of CD14+ HLA-DRlo/neg monocytes in the peripheral blood of OS patients has previously been shown to be immunosuppressive in a variety of cancers such as prostate cancer, non-Hodgkin lymphoma (NHL), glioblastoma multiforme, and chronic lymphocytic leukemia [16, 20–22].